.png){kind=icon}
返回
Developing drugs for developing countries
.png){kind=icon}
OA
AI
DOI：10.1377/hlthaff.25.2.313.png)
.png){kind=icon}
.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
Infectious and parasitic diseases create enormous health burdens, but because most of the people suffering from these diseases are poor, little is invested in developing treatments. We propose that developers of treatments for neglected diseases receive a priority review voucher. The voucher could save an average of one year of U.S. Food and Drug Administration (FDA) review and be sold by the developer to the manufacturer of a blockbuster drug. In a well-functioning market, the voucher would speed access to highly valued treatments. Thus, the voucher could benefit consumers in both developing and developed countries at relatively low cost to the taxpayer.
Keyword:
PHARMACEUTICALS
INNOVATION
MEDICINES
COMPANIES
DISEASES
PATENTS
PRICE
AI总结
对已上传原文的论文进行重点信息的提取，主要内容包括：简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。
期刊
IF:
8.1
论文数:
9.9K
被引数:
1.9W
机构
暂无机构信息
引用论文
How do patents and economic policies affect access to essential medicines in developing countries?.png)
HEALTH AFFAIRS
HEALTH AFFAIRSIF8.1
PREAI
分享收藏分享收藏Vaccine advance-purchase agreements for low-income countries: Practical issuesHEALTH AFFAIRS
HEALTH AFFAIRSIF8.1
PREAI
分享收藏分享收藏
查看更多内容